Alzheimer's Disease
Areas of Partnership Interest
- Disease-modifying therapy that slows disability progression or restores function
- Preclinical animal models that predict efficacy and/or clinical functional outcomes
- Surrogate/translational markers/endpoints/diagnostic
- Understanding the science underlying progression
- Treatment for the cognitive symptoms of Alzheimer's disease
- Diagnostic of prodromal and presymptomatic Alzheimer's disease
- Understanding the science underlying progression
Kelly Longo
Submit your idea
"Pfizer is committed to flexible, transparent and mutually beneficial long-term relationships with its partners. By joining forces, we can bring quality therapies to patients worldwide. Let's work together for a healthier world."
—Bill Ringo, Senior Vice President,
Worldwide Business Development
Strategy & Innovation
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2009 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
